BioVersys AG

BIOV

CH0210362643

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 11:20:00 2026-06-17 am EDT			5-day change	1st Jan Change
27.00 ^CHF	+0.37%		-1.11%	+9.43%

Apr. 30	Bioversys Ag Approves Election of Simona Skerjanec as Members of the Board of Directors	CI
Apr. 22	BioVersys Completes Phase 1 Safety, Pharmacokinetic Trial for BV100 in China	MT

Bioversys Ag Approves Election of Simona Skerjanec as Members of the Board of Directors

Published on 04/30/2026 at 01:00 pm EDT

S&P Capital IQ

BIOVERSYS AG

+0.37%

BioVersys AG announced at the AGM held on April 30, 2026, approved election of Ms. Simona Skerjanec as Members of the Board of Directors.

Latest news about BioVersys AG

Apr. 30	Bioversys Ag Approves Election of Simona Skerjanec as Members of the Board of Directors	CI
Apr. 22	BioVersys Completes Phase 1 Safety, Pharmacokinetic Trial for BV100 in China	MT
Apr. 22	BioVersys AG Completes BV100 Phase 1 Clinical Trial In China	CI
Apr. 16	BioVersys AG Announces First Patient First Visit In HABP/VABP Pivotal Phase 3 RIV-TARGET Trial Of BV100	CI
Apr. 15	Bioversys AG Presents Data on Clinical and Preclinical Pipeline Programs At ESCMID Global 2026	CI
Apr. 13	Bioversys Ag Publishes Pre-Clinical Data of Alpe Drug Combination in Nature Communications	CI
Apr. 07	Dr. William Jenkins Will Not Stand for Re-Election as A Member of the Board of Directors of BioVersys AG	CI
Apr. 02	Bioversys Appoints Anca Cighi as Head of Investor Relations and Communications	CI
Mar. 31	BioVersys Partners with Hackensack Meridian Health for Ansamycin Drug Research	MT
Mar. 31	Bioversys and Hackensack Meridian Health Enter Exclusive Ansamycin Drug Discovery Collaboration	CI
Mar. 18	BioVersys AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 18	BioVersys AG, 2025 Earnings Call, Mar 18, 2026
Mar. 18	BioVersys expects total operating loss of CHF 40-45 mln for FY2026	RE
Mar. 18	BioVersys AG Provides Earnings Guidance for the Full Year 2026	CI
Mar. 18	BioVersys' FY25 Loss Widens; Operating Income Rises	MT

BioVersys AG is a Switzerland based company engaged in the development of biopharmaceuticals. The Company focuses on developing antibacterial therapies to address antimicrobial resistance (AMR), particularly targeting pathogens identified as critical by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Their key product is BV100, which is a clinical-stage antibacterial compound. It is a small-molecule therapeutic designed to treat serious hospital infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) lung and bloodstream infections. The primary goal of this product is to reduce mortality in intensive care patients where current treatments are ineffective. The Company's portfolio includes also other medicines in various stages of development: BV200, Alpibectir, BV500, BV Discovery.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company